Recent advances in lung cancer treatment are improving survival and overall quality of life in patients with non–small-cell lung cancer (NSCLC) and small-cell lung cancer (SCLC). Lung Cancer Case Files: Current Strategies to Optimize Therapy, a free CME CD-ROM, focuses on the very latest advances in lung cancer management, including strategies for improved diagnosis, staging, and treatment. In this case-based educational activity, we discuss important data on lung cancer treatment—including the newest research—and formulate specific patient-care strategies illustrated in sample clinical cases. Each case highlights therapeutic decisions that aim to improve tumor response, survival, and overall quality of life, including decisions regarding first- and second-line therapy, the optimal duration of therapy, and options for palliative care.

Skeletal complications of malignancy—bone pain, pathologic fractures, spinal cord compression, and hypercalcemia—complicate the clinical course of lung cancer in many patients. Therefore, controlling bone metastases, which develop in approximately 30% to 65% of patients with lung cancer, is of paramount importance for improving quality of life. New data indicate that bisphosphonates reduce the risk of skeletal complications in lung cancer patients with bone metastases. In Lung Cancer Case Files: Current Strategies to Optimize Therapy, we explore how to translate these data into practical clinical recommendations relevant to your own patients.

It is my pleasure to share these important advances with you. I trust you will find this up-to-date information relevant to your clinical practice and of hope to your patients with lung cancer.

Sincerely,

Corey J. Langer, MD, FRACP
Chair

top

CHAIR

This activity is designed for clinicians who specialize in the treatment of lung cancer.

Activity Goal

The goal of this activity is to provide an overview of current lung cancer therapies using case-based scenarios, with a focus on bone metastases and the latest developments in preventing related skeletal complications using bisphosphonate therapies.

Learning Objectives

At the end of Lung Cancer Case Files, the physician should be able to:

• Review current data on the safety and efficacy of the newest therapeutic strategies for the treatment of small-cell and non–small-cell lung cancer.
• Apply evidence-based guidelines for management of patients with early and late stages of lung cancer.
• Develop individualized treatment plans to help reduce the occurrence of skeletal-related events (SREs) in patients with lung cancer.

top

CME Information

Statement of Accreditation

Projects In Knowledge is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation

Projects In Knowledge designates this educational activity for a maximum of 1.0 Category 1 credit toward the AMA Physician's Recognition Award. Each physician should claim only those credits that he/she actually spent in the activity.

This activity is planned and implemented as an independent CME activity in accordance with the ACCME Essential Areas and Policies.

Successful completion for up to 1.0 hour of CME credit requires a passing score of 70% or higher on the posttest. Full instructions for submission are included on the posttest at the end of the enduring material.

Disclosure Information

The Disclosure Policy of Projects In Knowledge requires that faculty participating in a CME activity disclose to the audience: any significant relationship they may have with a pharmaceutical or medical equipment company, product, or service that may be mentioned as part of their presentation; any relationship with the commercial supporter of this activity; if discussion includes 1) therapies that are unapproved for use or are investigational; 2) ongoing research; or 3) preliminary data. Faculty will disclose such discussion.

For complete prescribing information on the products discussed during this CME activity, please see your current Physicians' Desk Reference (PDR).

Corey J. Langer, MD, FRACP, has received grant/research support from and is a consultant for Novartis Pharmaceuticals Corporation. Dr. Langer has disclosed that he will reference unlabeled/unapproved use of zoledronic acid.

Peer Reviewer is on the speakers bureau of Aventis Pharmaceuticals Inc; and has received honoraria from Genentech, Inc.

The opinions expressed in this activity are those of the faculty and do not necessarily reflect those of Projects In Knowledge.

This CME activity is provided by Projects In Knowledge solely as an educational service. Specific patient care decisions are the responsibility of the physician caring for the patient.

Peer Review process directed by the University of Pennsylvania School of Medicine Office of CME. To find out more information click here.

Order Your Interactive
CD-ROM Today

This activity is designed for clinicians who specialize in the treatment of lung cancer.

Activity Goal

The goal of this activity is to provide an overview of current lung cancer therapies using case-based scenarios, with a focus on bone metastases and the latest developments in preventing related skeletal complications using bisphosphonate therapies.